From November 14 to 16, the 27th China Hi-Tech Fair (CHTF) was held in Shenzhen. As a national high-tech enterprise, Zhongke Health Industry Group (hereinafter referred to as Zhongke Group) showcased a number of its scientific research achievements at the fair. Thanks to its outstanding performance in scientific and technological innovation in the modern traditional Chinese medicine and big health industry, Zhongke Group was awarded the “Excellent Science and Technology Innovation Enterprise Award” by the organizing committee, and its core product — Zhongke Sairuosi Brand Ganoderma Spore Oil, won the “Excellent Scientific Research Achievement Innovation Award”, making the group a highlight of this year’s fair.
Outstanding Scientific and Technological Innovation Enterprise Award
Excellent Scientific Research Achievement Innovation Award
As a “full-attendance participant” of the CHTF, Zhongke Group has taken part in the fair in full for 27 consecutive years. At this year’s exhibition, the Group highlighted a series of core products including Ganoderma Spore Oil and Lycopene, covering multiple health fields such as immune regulation and tumor prevention and treatment, and presented its latest scientific research achievements in the modernization, internationalization and standardization of traditional Chinese medicine.
Founded in 1984, Zhongke Group has always adhered to driving development through scientific and technological innovation. In 1999, the Group successfully developed Ganoderma Spore Oil and realized its industrialization, driving the upgrading of the ganoderma industry. Up to now, Zhongke has obtained a total of 234 authorized patents, including 65 national invention patents (2 international PCT patents). Its ganoderma spore extraction technology has been recognized as a high-value patent, and the Group has been selected into the cultivation database of national model enterprises for patent industrialization.
Zhongke Group is actively integrating global resources by building high-end raw material bases in the United States, Canada, Israel and other regions. Relying on Zhongke Health International (New York) Co., Ltd., it has set up an overseas R&D center, whose project has been selected into the International Science and Technology Cooperation Program of Jiangsu Province. In addition, Zhongke has carried out clinical research on Compound Ganoderma Spore Capsules in cooperation with Memorial Sloan Kettering Cancer Center (MSKCC), a world-renowned authoritative cancer research institution, and has continuously promoted the international recognition of the modernization of traditional Chinese medicine.
Standard leadership is an important path for Zhongke to drive the high-quality development of the industry. Up to now, Zhongke has presided over and participated in the formulation of a total of 93 various standards, including 1 international standard and 25 national standards, helping Chinese health products enhance their international competitiveness with high standards.
The 27th CHTF has become a concentrated display of Zhongke Group’s scientific research and industrialization achievements over the past 41 years. Looking ahead, the enterprise will continue to deepen scientific and technological innovation and international cooperation, accelerate the modernization and internationalization of traditional Chinese medicine, and inject scientific and technological impetus into the construction of “Healthy China”.
EN 
CN